The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Open accessAbstract
Cancer cells have metabolic dependencies that distinguish them from their normal counterparts. Among these dependencies is an increased use of the amino acid glutamine to fuel anabolic processes. Indeed, the spectrum of glutamine-dependent tumours and the mechanisms whereby glutamine supports cancer metabolism remain areas of active investigation. Here we report the identification of a non-canonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that is required for tumour growth. Whereas most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into α-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle, PDAC relies on a distinct pathway in which glutamine-derived aspartate is transported into the cytoplasm where it can be converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate is converted into malate and then pyruvate, ostensibly increasing the NADPH/NADP(+) ratio which can potentially maintain the cellular redox state. Importantly, PDAC cells are strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway leads to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions also results in a pronounced suppression of PDAC growth in vitro and in vivo. Furthermore, we establish that the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in PDAC, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway. The essentiality of this pathway in PDAC and the fact that it is dispensable in normal cells may provide novel therapeutic approaches to treat these refractory tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, depending on the tissue of origin, cancer cells use various routes of glutamine metabolism. Some have been shown to require an exogenous glutamine supply for malignant proliferation [71,72], whereas others do not [73] and can synthesize it de novo [74].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [73]
In the citing paper
“For instance, KRAS-dependent upregulation of Glutamate Oxaloacetate Transaminase 1,2. (GOT) expression in pancreatic cancer facilitates production of aspartate for nucleotide biosynthesis, and allows NADPH generation via ME157,58 (Fig 2).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [57]
In the citing paper
“Mouse PDAC tumors driven by mutant Kras also experience metabolic alteration and are dependent on glucose and glutamine (73, 77).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [77]
In the citing paper
“combining inhibition of glycolysis with blockade of KRAS effector signaling pathways has shown efficacy in culture and xenograft models197”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“metabolic inhibition approaches combined with RAS pathway inhibitors have shown strong pre-clinical data and are currently in clinical trials197,224,225”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“However, under normal and glucose-replete conditions, transamination is the dominant reaction that drives glutamine anaplerosis in cultured cells (79, 80, 81, 82).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Self-citationSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Cited by
Sorted by citations
Items 101–200 of 1,004
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Pan, M., Reid, M. A., Lowman, X. H., Kulkarni, R. P., Tran, T. Q., Liu, X., Yang, Y., Hernandez-Davies, J. E., Rosales, K. K., Li, H., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3410 · Cited by 368
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect
Sun, L., Suo, C., Li, S., Zhang, H., & Gao, P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.005 · Cited by 374
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
Sun, R. C., & Denko, N. C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.022 · Cited by 344
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348
Self-citationYang, L., Moss, T., Mangala, L. S., Marini, J., Zhao, H., Wahlig, S., Armaiz‐Pena, G., Jiang, D., Achreja, A., Win, J., et al. (2014) · Molecular Systems Biology · doi:10.1002/msb.20134892 · Cited by 326
Role of glutamine and interlinked asparagine metabolism in vessel formation
Huang, H., Vandekeere, S., Kalucka, J., Bierhansl, L., Zecchin, A., Brüning, U., Visnagri, A., Yuldasheva, N., Goveia, J., Cruys, B., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201695518 · Cited by 320
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 344
Endothelial Cell Metabolism in Health and Disease
Rohlenová, K., Veys, K., Santos, I. M., Bock, K. D., & Carmeliet, P. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.010 · Cited by 351
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 349
Self-citationMullarky, E., Lucki, N. C., Beheshti Zavareh, R., Anglin, J. L., Gomes, A. P., Nicolay, B. N., Wong, J. C. Y., Christen, S., Takahashi, H., Singh, P. K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521548113 · Cited by 333
Self-citationTargeting mitochondrial metabolism for precision medicine in cancer
Sainero‐Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., & Arsenian‐Henriksson, M. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01022-y · Cited by 338
Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism
Biancur, D. E., Paulo, J. A., Małachowska, B., Quiles Del Rey, M., Sousa, C. M., Wang, X., Sohn, A. S. W., Chu, G. C., Gygi, S. P., Harper, J. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms15965 · Cited by 315
Self-citationCPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
Kim, J., Hu, Z., Cai, L., Li, K., Choi, E., Faubert, B., Bezwada, D., Rodriguez-Canales, J., Villalobos, P., Lin, Y.-F., et al. (2017) · Nature · doi:10.1038/nature22359 · Cited by 325
Mukhopadhyay, S., Goswami, D., Adiseshaiah, P. P., Burgan, W., Yi, M., Guerin, T. M., Kozlov, S. V., Nissley, D. V., & McCormick, F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1363 · Cited by 279
Targeting Glutamine Metabolism for Cancer Treatment
Choi, Y., & Park, K. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.178 · Cited by 335
Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells
Coloff, J. L., Murphy, J. P., Braun, C. R., Harris, I. S., Shelton, L. M., Kami, K., Gygi, S. P., Selfors, L. M., & Brugge, J. S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.016 · Cited by 288
The enhancement of glycolysis regulates pancreatic cancer metastasis
Yang, J., Ren, B., Yang, G., Wang, H., Chen, G., You, L., Zhang, T., & Zhao, Y. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03278-z · Cited by 347
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 316
Muir, A., Danai, L. V., Gui, D. Y., Waingarten, C. Y., Lewis, C. A., & Vander Heiden, M. G. (2017) · eLife · doi:10.7554/elife.27713 · Cited by 311
α-Ketoglutarate links p53 to cell fate during tumour suppression
Morris, J. P., Yashinskie, J. J., Koche, R., Chandwani, R., Tian, S., Chen, C.-C., Baslan, T., Marinkovic, Z. S., Sánchez-Rivera, F. J., Leach, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1577-5 · Cited by 296
Lim, J. K. M., Delaidelli, A., Minaker, S. W., Zhang, H., Čolović, M., Yang, H., Negri, G. L., von Karstedt, S., Lockwood, W. W., Schaffer, P. C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821323116 · Cited by 321
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290
Dysregulated metabolism contributes to oncogenesis
Hirschey, M. D., DeBerardinis, R. J., Diehl, A. M., Drew, J. E., Frezza, C., Green, M. F., Jones, L. W., Ko, Y. H., Le, A., Lea, M. A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.10.002 · Cited by 316
Self-citationTargeting amino acid metabolism for cancer therapy
Lukey, M. J., Katt, W. P., & Cerione, R. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.12.003 · Cited by 293
Ventura, R., Mordec, K., Waszczuk, J., Wang, Z., Lai, J., Fridlib, M., Buckley, D., Kemble, G., & Heuer, T. S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.020 · Cited by 301
Defining the Metabolome: Size, Flux, and Regulation
Zamboni, N., Saghatelian, A., & Patti, G. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.021 · Cited by 299
Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer
Li, J., Gu, D., Lee, S. S.-Y., Song, B., Bandyopadhyay, S., Chen, S., Konieczny, S. F., Ratliff, T. L., Liu, X., Xie, J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.168 · Cited by 300
Metabolism shapes the tumor microenvironment
Reina‐Campos, M., Moscat, J., & Díaz-Meco, M. T. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.05.006 · Cited by 292
Shiratori, R., Furuichi, K., Yamaguchi, M., Miyazaki, N., Aoki, H., Chibana, H., Ito, K., & Aoki, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-55296-3 · Cited by 297
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Yu, X., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 313
Glucose and Glutamine Metabolism Regulate Human Hematopoietic Stem Cell Lineage Specification
Oburoglu, L., Tardito, S., Fritz, V., de Barros, S. C., Mérida, P., Craveiro, M., Mamede, J. I., Cretenet, G., Mongellaz, C., An, X., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.06.002 · Cited by 312
Galan-Cobo, A., Sitthideatphaiboon, P., Qu, X., Poteete, A., Pisegna, M. A., Tong, P., Chen, P.-H., Boroughs, L. K., Rodriguez, M. L. M., Zhang, W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3527 · Cited by 292
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy
Yang, W., Qiu, Y., Stamatatos, O. T., Janowitz, T., & Lukey, M. J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.003 · Cited by 308
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
Najumudeen, A. K., Ceteci, F., Fey, S. K., Hamm, G. R., Steven, R. T., Hall, H., Nikula, C. J., Dexter, A., Murta, T., Race, A. M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00753-3 · Cited by 291
Liou, G.-Y., Döppler, H., DelGiorno, K. E., Zhang, L., Leitges, M., Crawford, H. C., Murphy, M. P., & Storz, P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.029 · Cited by 270
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Santana-Codina, N., Roeth, A. A., Zhang, Y., Yang, A., Mashadova, O., Asara, J. M., Wang, X., Bronson, R. T., Lyssiotis, C. A., Ying, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07472-8 · Cited by 252
Self-citationPoursaitidis, I., Wang, X., Crighton, T., Labuschagne, C. F., Mason, D. Y., Cramer, S. L., Triplett, K., Roy, R., Pardo, O. E., Seckl, M. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.054 · Cited by 273
Self-citationThe functional roles of TCA cycle metabolites in cancer
Eniafe, J., & Jiang, S. (2021) · Oncogene · doi:10.1038/s41388-020-01639-8 · Cited by 289
Tumour-specific proline vulnerability uncovered by differential ribosome codon reading
Loayza‐Puch, F., Rooijers, K., Buil, L. C. M., Zijlstra, J., Vrielink, J. A. F. O., Lopes, R., Ugalde, A. P., Breugel, P. C. V., Hofland, I., Wesseling, J., et al. (2016) · Nature · doi:10.1038/nature16982 · Cited by 274
Cancer, Oxidative Stress, and MetastasisPreprint
Gill, J. G., Piskounova, E., & Morrison, S. J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030791 · Cited by 278
Childs, E. J., Mocci, E., Campa, D., Bracci, P. M., Gallinger, S., Goggins, M., Li, D., Neale, R. Ε., Olson, S. H., Scélo, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3341 · Cited by 265
Zhang, K., Xu, H., Jia, X., Chen, Y., Ma, M., Sun, L., & Chen, H. (2016) · ACS Nano · doi:10.1021/acsnano.6b04921 · Cited by 265
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature · doi:10.1038/nature21052 · Cited by 264
Self-citationLuca, A. D., Fiorillo, M., Peiris‐Pagès, M., Ózsvári, B., Smith, D. L., Sánchez‐Alvarez, R., Martinez‐Outschoorn, U., Cappello, A. R., Pezzi, V., Lisanti, M. P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4401 · Cited by 262
Csibi, A., Lee, G., Yoon, S.-O., Tong, H., Ilter, D., Elia, I., Fendt, S., Roberts, T. M., & Blenis, J. (2014) · Current Biology · doi:10.1016/j.cub.2014.08.007 · Cited by 253
RetractedMetabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
Shukla, S. K., Gebregiworgis, T., Purohit, V., Chaika, N. V., Gunda, V., Radhakrishnan, P., Mehla, K., Pipinos, I. I., Powers, R., Yu, F., et al. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-18 · Cited by 256
GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis
Kremer, D. M., Nelson, B. S., Lin, L., Yarosz, E. L., Halbrook, C. J., Kerk, S. A., Sajjakulnukit, P., Myers, A. L., Thurston, G., Hou, S. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24859-2 · Cited by 268
Self-citationPenny, H. L., Sieow, J. L., Adriani, G., Yeap, W. H., See, P., Luis, B. S., Lee, B. T. K., Lee, T. K., Mak, S. Y., Ho, Y. S., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1191731 · Cited by 261
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 260
Pochini, L., Scalise, M., Galluccio, M., & Indiveri, C. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00061 · Cited by 264
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., & Toker, A. (2016) · Nature Cell Biology · doi:10.1038/ncb3341 · Cited by 249
Self-citationHeterogeneity in Cancer Metabolism: New Concepts in an Old Field
Gentric, G., Mieulet, V., & Mechta‐Grigoriou, F. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6750 · Cited by 248
Elgogary, A., Xu, Q., Poore, B., Alt, J., Zimmermann, S. C., Zhao, L., Fu, J., Chen, B., Xia, S., Liu, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611406113 · Cited by 234
Glutamine Metabolism in Cancer
Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 242
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine
Lemberg, K. M., Vornov, J. J., Rais, R., & Slusher, B. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1148 · Cited by 234
Cystathionine-β-synthase: Molecular Regulation and Pharmacological Inhibition
Zuhra, K., Augsburger, F., Majtán, T., & Szabó, C. (2020) · Biomolecules · doi:10.3390/biom10050697 · Cited by 252
Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer
Recouvreux, M. V., & Commisso, C. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00261 · Cited by 237
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Édouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 248
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T. Y., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 246
Self-citationGwinn, D. M., Lee, A. G., Briones-Martin-del-Campo, M., Conn, C. S., Simpson, D. R., Scott, A. I., Le, A., Cowan, T. M., Ruggero, D., & Sweet-Cordero, E. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.003 · Cited by 230
Sayin, V. I., LeBoeuf, S. E., Singh, S. X., Davidson, S. M., Biancur, D., Guzelhan, B. S., Alvarez, S. W., Wu, W. L., Karakousi, T. R., Zavitsanou, A. M., et al. (2017) · eLife · doi:10.7554/elife.28083 · Cited by 231
Gaude, E., Schmidt, C., Gammage, P. A., Dugourd, A. J. F., Blacker, T. S., Peak‐Chew, S., Sáez-Rodríguez, J., O'Neill, J. S., Szabadkai, G., Minczuk, M. A., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.034 · Cited by 235
The Therapeutic Potential of Cystathionine β-Synthetase/Hydrogen Sulfide Inhibition in Cancer
Hellmich, M. R., Coletta, C., Chao, C., & Szabó, C. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5933 · Cited by 234
TAp73 enhances the pentose phosphate pathway and supports cell proliferation
Du, W., Jiang, P., Mancuso, A., Stonestrom, A. J., Brewer, M. D., Minn, A. J., Mak, T. W., Wu, M., & Yang, X. (2013) · Nature Cell Biology · doi:10.1038/ncb2789 · Cited by 238
Ma, G., Zhang, Z., Li, P., Zhang, Z., Zeng, M., Liang, Z., Li, D., Wang, L., Chen, Y., Liang, Y., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00909-0 · Cited by 241
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3
Tajan, M., Hock, A. K., Blagih, J., Robertson, N. A., Labuschagne, C. F., Kruiswijk, F., Humpton, T. J., Adams, P. D., & Vousden, K. H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.005 · Cited by 230
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
Huang, X., Gan, G., Wang, X., Xu, T., & Xie, W. (2019) · Autophagy · doi:10.1080/15548627.2019.1580105 · Cited by 238
Self-citationArginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer
Wang, Y.-P., Zhou, W., Wang, J., Huang, X., Zuo, Y., Wang, T.-S., Gao, X. J., Xu, Y., Zou, S., Liu, Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.028 · Cited by 230
Cancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 236
Grasso, D., Zampieri, L. X., Capelôa, T., de Velde, J. A. V., & Sonveaux, P. (2020) · Cell Stress · doi:10.15698/cst2020.06.221 · Cited by 239
The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · The EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 235
Yang, H., Zhou, L., Shi, Q., Zhao, Y., Lin, H., Zhang, M., Zhao, S., Yang, Y. A., Ling, Z., Guan, K., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591041 · Cited by 225
Metabolic Dependencies in RAS -Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 230
Self-citationTargeting glutamine transport to suppress melanoma cell growth
Wang, Q., Beaumont, K. A., Otte, N. J., Font, J. S., Bailey, C. G., van Geldermalsen, M., Sharp, D. M., Tiffen, J. C., Ryan, R. M., Jormakka, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28749 · Cited by 227
Eisenreich, W., Rudel, T., Heesemann, J., & Goebel, W. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00042 · Cited by 229
Francescone, R., Costa, D. B. V., Franco‐Barraza, J., Wagner, J., Muir, A., Lau, A. N., Gabitova, L., Pazina, T., Gupta, S., Luong, T., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0775 · Cited by 227
mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
Pusapati, R. V., Daemen, A., Wilson, C., Sandoval, W. N., Gao, M., Haley, B., Baudy, A. R., Hatzivassiliou, G., Evangelista, M., & Settleman, J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.018 · Cited by 221
Oncogenic pathways and the electron transport chain: a dangeROS liaison
Raimondi, V., Ciccarese, F., & Ciminale, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0651-y · Cited by 232
Ma, L., Chen, T., Zhang, X., Miao, Y., Tian, X., Yu, K., Xu, X., Niu, Y., Guo, S., Zhang, C., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101801 · Cited by 223
Baek, G., Tse, Y. F., Hu, Z., Cox, D., Buboltz, N., McCue, P. A., Yeo, C. J., White, M. A., DeBerardinis, R. J., Knudsen, E. S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.025 · Cited by 227
Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0297 · Cited by 213
Self-citationPancreatic Cancer Metabolism: Breaking It Down to Build It Back Up
Perera, R. M., & Bardeesy, N. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0671 · Cited by 218
Self-citationChen, Q., Kirk, K., Shurubor, Y. I., Zhao, D., Arreguin, A. J., Shahi, I., Valsecchi, F., Primiano, G., Calder, E. L., Carelli, V., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.002 · Cited by 210
The Diverse Functions of Non-Essential Amino Acids in Cancer
Choi, B.-H., & Coloff, J. L. (2019) · Cancers · doi:10.3390/cancers11050675 · Cited by 213
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
Sharma, N. S., Gupta, V. K., Garrido, V. T., Hadad, R., Durden, B. C., Kesh, K., Giri, B., Ferrantella, A., Dudeja, V., Saluja, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127515 · Cited by 203
Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer
Lien, E. C., Lyssiotis, C. A., & Cantley, L. C. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_3 · Cited by 217
Self-citationRas and Rap1: A tale of two GTPases
Shah, S. K., Brock, E. J., Ji, K., & Mattingly, R. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 217
Huang, J., Jiang, G., Song, Q., Gu, X. Q., Meng, H., Wang, X.-L., Song, H., Chen, L., Lin, Y., Jiang, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 212
Self-citationKarasinska, J. M., Topham, J. T., Kalloger, S. E., Jang, G. H., Denroche, R. E., Culibrk, L., Williamson, L. M., Wong, H., Lee, M. K. C., O'Kane, G. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1543 · Cited by 215
Origin and Consequences of Necroinflammation
Sarhan, M., Land, W. G., Tonnus, W., Hugo, C., & Linkermann, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00041.2016 · Cited by 217
The role of YAP/TAZ activity in cancer metabolic reprogramming
Zhang, X., Zhao, H., Li, Y., Xia, D., Yang, L., Ma, Y., & Li, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0882-1 · Cited by 212
Oncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer
Humpton, T. J., Alagesan, B., DeNicola, G. M., Lu, D., Yordanov, G. N., Leonhardt, C. S., Yao, M. A., Alagesan, P., Zaatari, M. N., Park, Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1409 · Cited by 198
Tong, Y., Guo, D. S., Lin, S., Liang, J., Yang, D., Ma, C., Shao, F., Li, M., Yu, Q., Jiang, Y., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.04.002 · Cited by 209
Critical Functions of the Lysosome in Cancer Biology
Davidson, S. M., & Heiden, M. G. V. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103101 · Cited by 214
Ferroptosis as a potential target for cancer therapy
Chen, Z., Wang, W., Razak, S. R. A., Han, T., Ahmad, N. H., & Li, X. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05930-w · Cited by 223
Świerczyński, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2279 · Cited by 203
Metadata
- Authors
- Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., DePinho, R. A., Cantley, L. C., & Kimmelman, A. C.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts General Hospital (US)
- Harvard University (US)
- Corresponding author
- Cantley, Lewis C.
- Kimmelman, Alec C.
- ORCID
- Venue
- Nature
- Published
- 2013-03-27
- Volume
- 496
- Issue
- 7443
- Pages
- 101-105
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656466
- OpenAlex
- W2014988241
- Cited by
- 1,990
- References
- 27
- Citations by year
- 2026: 130 · 2025: 143 · 2024: 138 · 2023: 169 · 2022: 193 · 2021: 209 · 2020: 169 · 2019: 162 · 2018: 141 · 2017: 144 · 2016: 152 · 2015: 112 · 2014: 95 · 2013: 31
- FWCI
- 45.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-06-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (T32CA009382, R01CA157490, P01CA120964, P01CA117969, P30CA006516)
- National Institute of General Medical Sciences (R01GM056203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, glutamine metabolism, KRAS, tumor metabolic reprogramming, oxaloacetate, NADPH/NADP+ ratio, redox homeostasis, glutamine deprivation, reactive oxygen species, glutathione, tumor growth
- MeSH terms
- Adenocarcinoma, Aspartate Aminotransferases, Citric Acid Cycle, Glutamate Dehydrogenase, Glutamine, Homeostasis, Humans, Ketoglutaric Acids, Oncogenes, Oxidation-Reduction, Pancreatic Neoplasms, Proto-Oncogene Proteins, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), Reactive Oxygen Species, ras Proteins, Cell Line, Tumor, Cell Proliferation, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
